C07D267/22

Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors

The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: ##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors

The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: ##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

15-PGDH INHIBITOR

[Problem]

To provide a compound having a 15-PGDH inhibitory effect.

[Solution]

A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.

15-PGDH INHIBITOR

[Problem]

To provide a compound having a 15-PGDH inhibitory effect.

[Solution]

A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.

BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS

The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II:

##STR00001##

where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS

The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II:

##STR00001##

where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

NEFOPAM DOSAGE FORMS AND METHODS OF TREATMENT
20230364108 · 2023-11-16 ·

Dosage forms containing nefopam, nefopam metabolite, nefopam prodrug, isomers thereof or combinations of the foregoing, optionally an acid, and optionally an opioid analgesic and/or NSAID, and associated methods for treating various types of pain in patients.

NEFOPAM DOSAGE FORMS AND METHODS OF TREATMENT
20230364108 · 2023-11-16 ·

Dosage forms containing nefopam, nefopam metabolite, nefopam prodrug, isomers thereof or combinations of the foregoing, optionally an acid, and optionally an opioid analgesic and/or NSAID, and associated methods for treating various types of pain in patients.

BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS

The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II:

##STR00001##

where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS

The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II:

##STR00001##

where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.